Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 3, 2011, Pages 476-481

  Goel, Madhu ^a   Agrawal, Dhamita ^a   Natu, S ^a   Goel, Apul ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Hepsin; immunohistochemistry; prostate cancer

Indexed keywords

HEPSIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; POSTOPERATIVE PERIOD; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; SERUM;

EID: 80053930261     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.85078     Document Type: Article

References (16)

1. Emerging biomarkers for the detection and management of prostate carcinoma. chapter 19, Biopsy Interpretation Series. Biopsy Interpretation of the Prostate. In: Epstein JI and Netto GJ, editors, 4th ed., USA: Lippincott Williams and Wilkins; 2008.p.330-9.
2. Epstein JI, Potter SR. The pathologic interpretation and significance of prostate needle biopsy findings: Implications and current controversies. J Urol 2001;166:402-10.
3. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004;172:1297-301.
4. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 1999;162:293-306.
5. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008;54:1951-60.
6. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
7. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-6.
8. Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, et al. Detection of early prostate cancer using a hepsin-targetted imaging agent. Cancer Res 2008;68:2286-91.
9. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, et al. Human prostate cancer and benign prostatic hyperplasia molecular dissection by gene expression profiling. Cancer Res 2001; 61:4683-8.
10. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6:185-95.
11. Pal P, Xi H, Kaushal R, Sun G, Jin CH, Jin L, et al. Variants in the Hepsin genes are associated with prostate cancer in men of the European origin. Hum Genet 2006;120:187-92.
12. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. Hepsin inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002;62:6812-6.
13. Xuan JA, Schneider D, Toy P, Lin R, Newton A, Zhu Y, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 2006;66:3611-9.
14. Wu Q, Parry G. Hepsin and prostate cancer. Front Biosci 2007;12:5052-9.
15. Chevillet JR, Park GJ, Bedalov A, Simon JA, Vasioukhin VI. Identification and characterization of small-molecule inhibitors of hepsin. Mol Cancer Ther 2008;7:3343-51.
16. Huang HC, Zheng S, VanBuren V, Zhao Z. Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat 2010;9:219-30.